Andrew GoodmanAndrewGoodman
Partner, Mergers & Acquisitions
Andrew Goodman is a partner in the Mergers & Acquisitions and Shareholder Activism & Takeover Defense practices and is based in the firm’s Boston and New York offices. His practice focuses on friendly and hostile public company M&A, corporate governance, shareholder activism defense and contested situations. He works with clients in a variety of industries, with substantial experience in life sciences and healthcare, technology and REITs.
REPRESENTATIONS de
Ligand Pharmaceuticals in its $739 million acquisition of XOMA Royalty.
Jasper Therapeutics in its simultaneous sign and close reverse merger with Kira Pharmaceuticals, concurrent $123 million PIPE financing and contingent value rights (CVRs).
Deerfield Management Company, in its capacity as significant stockholders of Actio Biosciences in its pending acquisition by Jazz Pharmaceuticals for $820 million upfront and up to $500 million in contingent consideration.
Orchard Therapeutics in its cross-border sale to Kyowa Kirin for $390 million in upfront cash plus CVRs.
Scipher Medicine in its pending cross-border reverse merger with Chemomab Therapeutics, concurrent financing and CVRs.
EQRx in its sale to Revolution Medicines in an all-stock transaction to transfer more than $1 billion in capital.
ACELYRIN in its all-stock combination with Alumis.
Graphite Bio in its reverse merger with LENZ Therapeutics and concurrent private placement financing.
RA Capital Management in connection with Eliem Therapeutics’ acquisition of Tenet Medicines and concurrent $120 million private placement.
Korro Bio in its reverse merger with Frequency Therapeutics, concurrent $117 million private placement financing, and CVRs.
Forma Therapeutics in its $1.1 billion sale to Novo Nordisk.
Concert Pharmaceuticals in its cross-border sale to Sun Pharma for $576 million in upfront cash plus CVRs.
TCR² Therapeutics in its cross-border, all-stock combination with Adaptimmune Therapeutics.
Surface Oncology in its sale to Coherus BioSciences for stock consideration and CVRs.
Checkmate Pharmaceuticals in its $250 million sale to Regeneron Pharmaceuticals.
VBL Therapeutics in its reverse merger with Notable Labs and concurrent private placement financing.
Xeris Pharmaceuticals in its cross-border acquisition of Strongbridge Biopharma for stock and CVRs valued at $267 million.
EryDel in its cross-border sale to Quince Therapeutics.
Neos Therapeutics in its all-stock merger with Aytu BioScience.
PAREXEL in its $5 billion take-private sale to Pamplona Capital Management.
Ipsen in its cross-border acquisition of Clementia Pharmaceuticals for up to $1.3 billion in upfront cash and CVRs.
Dimension Therapeutics in its proposed sale to RegenxBio and subsequent acceptance of topping bid from, and $151 million sale to, Ultragenyx.
Ocera Therapeutics in its sale to Mallinckrodt for up to $117 million in upfront cash and CVRs.
Morgan Stanley in its role as financial adviser to Stemcentrx in its $5.8 billion sale to AbbVie.
Ocata Therapeutics in its $380 million sale to Astellas Pharma.
Teva Pharmaceutical Industries in its disposition of certain assets to Ignyta.
Concert Pharmaceuticals in its disposition of certain assets to Vertex Pharmaceuticals.
Zoll Medical in its $2.21 billion sale to Asahi Kasei.
Covidien in its $250 million acquisition of Somanetics.
Aerpio Pharmaceuticals in its reverse merger with Aadi Bioscience, concurrent $155 million PIPE financing, and CVRs.
resTORbio in its reverse merger with Adicet Bio, and CVRs.
Unum Therapeutics in its simultaneous sign and close reverse merger with Kiq, concurrent $104 million PIPE financing, and CVRs.
Anelixis Therapeutics in its simultaneous sign and close reverse merger with Novus Therapeutics, and concurrent $108 million PIPE financing.
Scienture in its simultaneous sign and close reverse merger with TRxADE HEALTH, and PIPE financing.
Zafgen in its reverse merger with Chondrial Therapeutics (operating as Larimar Therapeutics).
Inotek Pharmaceuticals in its reverse merger with Rocket Pharma.
Precipio Diagnostics in its reverse merger with Transgenomic and related financing transaction.
UniFirst in its pending $5.5 billion acquisition by Cintas.
Tri Pointe Homes in its $4.5 billion strategic combination with Sumitomo Forestry.
Heidrick & Struggles in its $1.3 billion take-private by Advent International and Corvex Private Equity.
Accelerant in its pending sale to Thoma Bravo in an all-cash transaction with an enterprise value of more than $4 billion.
Thoughtworks in its $1.75 billion take-private by Apax Funds.
Morgan Stanley serving as lead financial advisor to Equity Residential in its all-stock merger of equals with AvalonBay Communities, creating a combined company with an enterprise value of approximately $70 billion.
Morgan Stanley serving as exclusive financial adviser to Compass in connection with its combination with Anywhere Real Estate in an all-stock transaction valued at $10 billion.
Vine Hill Capital Investment in its business combination with CoinShares International, a leading global asset manager specializing in digital assets.
Virtusa in its $2 billion take-private sale to Baring Private Equity Asia.
Leaf Group in its $323 million sale to Graham Holdings.
LaSalle Hotel Properties in its response to unsolicited public acquisition proposals from Pebblebrook Hotel Trust, leading to its proposed $4.8 billion take-private sale to Blackstone, and subsequent acceptance of topping bid from, and $5.2 billion cash and shares acquisition by, Pebblebrook Hotel Trust.
Amplify Snack Brands (the maker of SkinnyPop popcorn) in its $1.6 billion sale to Hershey.
Monotype in its $825 million take-private sale to HGGC.
Control4 in its $680 million sale to SnapAV, a portfolio company of Hellman & Friedman.
Imprivata in its $544 million take-private sale to Thoma Bravo.
Opower in its $532 million sale to Oracle.
Xoom in its $890 million sale to PayPal.
Millennial Media in its $248 million sale to AOL.
Paydiant in its sale to PayPal.
High Liner Foods in its $230 million acquisition of Icelandic Group’s U.S. and Asia operations.
Salary.com in its sale to Kenexa.
The Princeton Review in its $170 million acquisition of Penn Foster Education Group.
Candela in its sale to Syneron Medical.
Honest Tea in connection with a strategic investment by Coca-Cola.
Inverness Medical Innovations in its $1.19 billion acquisition of Matria Healthcare.
Morgan Stanley Real Estate Fund in its $6.5 billion acquisition of Crescent Real Estate Equities.
Brookfield Properties in its $9.3 billion acquisition of Trizec Properties.
Beacon Capital Partners in its $4.8 billion sale of private investment funds to Broadway Real Estate Partners.
UniFirst in its proxy contest with Engine Capital.
Neuphoria Therapeutics in its defense against Lynx Capital.
Allied Gaming & Entertainment in its proxy contest and related litigation against Knighted Pastures, which sought unsuccessfully to replace a majority of the company’s board.
Culp in its cooperation agreement with 22NW.
Anika Therapeutics in its defenses against, and entry into cooperation agreements with, Caligan Partners.
Rapid Micro Biosystems in its defense of an unsolicited takeover proposal by Kennedy Lewis Management, and its adoption of a limited duration stockholder rights plan.
WisdomTree Investments in its defenses against, and entry into cooperation agreements with, ETFS Capital Limited and Lion Point Capital, and its adoption of a limited duration stockholder rights plan.
KVH Industries its defense against, and entry into cooperation agreement with, Black Diamond Capital Management, and its adoption of a limited duration stockholder rights plan.
Cedar Realty Trust in its defense against, and entry into cooperation agreements with, Camac Partners and Ewing Morris & Co.
Virtusa in its defense against, and entry into settlement agreement with, New Mountain Vantage Advisers.
Paramount Group in connection with an unsolicited acquisition proposal from Bow Street.
LaSalle Hotel Properties in its successful defense of activist campaigns led by HG Vora.
Monotype in its successful defense of a threatened proxy contest by Starboard Value.
Leaf Group in its successful defense of a threatened proxy contest by Osmium Partners.
AMAG Pharmaceuticals in its consent solicitation defense against, and entry into settlement agreement with, Caligan Partners.
Invesco Closed-end Funds trustees in response to shareholder proposals and nominations from, and entry into standstill agreement with, Saba Capital.
Cedar Realty Trust in the negotiation of a cooperation agreement with Snow Park Capital.
Cognizant in the negotiation of a cooperation agreement with Elliott Management.
PAREXEL in its defense of activist campaigns led by Corvex and Starboard Value.
A well-known closed-end fund in its response to shareholder proposals from, and entry into standstill agreement with, Saba Capital.
iRobot in its successful proxy contest concerning board representation against Red Mountain Capital.
CPS Technologies in its successful defense of a threatened proxy contest and "vote against" campaign by the Horton Group.
Brightcove in its entry into a cooperation agreement with, and subsequent successful defense of a threatened proxy contest by, Tenzing Global.
Monogram Residential Trust in its entry into a cooperation agreement with Snow Park Capital.
Relmada Therapeutics in its proxy contest and related litigation against Laidlaw, which sought unsuccessfully to replace a majority of the company’s board.
Lionbridge in its response to, and entry into a cooperation agreement with, Glen Capital Partners.
LoJack in its response to, and entry into a cooperation agreement with, Engine Capital.
Mac-Gray in its proxy contests against Moab Partners.
* Matters may have been handled prior to joining Paul Hastings.
RECOGNITION de
- Notable Practitioner
IFLR 1000
- Shareholder Activism
Legal 500
NEWS & THOUGHT LEADERSHIP de
ASSOCIATIONS de
Member
American Bar Association
Member
Boston Bar Association